Physician profile
Robert B Schlesinger
NPI 1225031172
$8,858.60
in general payments reported to CMS, 2019-2025
32 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $742 · 2021: $1,092 · 2022: $1,419 · 2023: $1,442 · 2024: $1,596 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,225 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.03 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,253.61 | 2019-2025 | |
| Amgen INC. | $914.45 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $773.72 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $761.05 | 2019-2024 | Xarelto |
| Pfizer INC. | $646.19 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $561.73 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $506.57 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.26 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $441.00 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Astellas Pharma US INC | $397.58 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $318.85 | 2022-2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $253.51 | 2019-2024 | |
| Amarin Pharma, INC. | $225.34 | 2019-2022 | |
| Abbott Laboratories | $197.75 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Philips North America LLC | $179.04 | 2022-2025 | Holter, (Ck4) Mcot, Extended Holter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $154.10 | 2020-2024 | Watchman Access System, Watchman Flx |
| Novo Nordisk INC | $119.22 | 2022-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $86.02 | 2019-2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $73.74 | 2024 | Arcalyst |
| Altathera Pharmaceuticals LLC | $72.65 | 2022-2023 | Sotalol Hydrochloride |
| Alnylam Pharmaceuticals INC. | $69.26 | 2024-2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $66.13 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $55.98 | 2022-2023 | Injectafer |
| Inspire Medical Systems, INC. | $55.55 | 2023-2025 | Inspire |
| Convatec INC. | $37.88 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.50 | 2022-2023 | |
| Esperion Therapeutics, INC. | $30.66 | 2023-2024 | Nexletol |
| Atricure, INC. | $28.78 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $20.92 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $18.19 | 2020 | |
| Lundbeck LLC | $17.34 | 2020 | |
| Althera Pharmaceuticals LLC | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.